Literature DB >> 20553310

The role of tau in Alzheimer's disease and related disorders.

Rodrigo Medeiros1, David Baglietto-Vargas, Frank M LaFerla.   

Abstract

Tau, the microtubule-associated protein, forms insoluble filaments that accumulate as neurofibrillary tangles in Alzheimer's disease (AD) and related tauopathies. Under physiological conditions, tau regulates the assembly and maintenance of the structural stability of microtubules. In the diseased brain, however, tau becomes abnormally hyperphosphorylated, which ultimately causes the microtubules to disassemble, and the free tau molecules aggregate into paired helical filaments. A large body of evidence suggests that tau hyperphosphorylation results from perturbation of cellular signaling, mainly through imbalance in the activities of different protein kinases and phosphatases. In AD, it appears that ß-amyloid peptide (Aß) plays a pivotal role in triggering this imbalance. In this review, we summarize our current understanding of the role of tau in AD and other tauopathies, and highlight key issues that need to be addressed to improve the success of developing novel therapies.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20553310      PMCID: PMC4072215          DOI: 10.1111/j.1755-5949.2010.00177.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  118 in total

Review 1.  Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation.

Authors:  Cheng-Xin Gong; Fei Liu; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  J Alzheimers Dis       Date:  2006-03       Impact factor: 4.472

2.  Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo.

Authors:  Norbert Zilka; Peter Filipcik; Peter Koson; Lubica Fialova; Rostislav Skrabana; Monika Zilkova; Gabriela Rolkova; Eva Kontsekova; Michal Novak
Journal:  FEBS Lett       Date:  2006-05-22       Impact factor: 4.124

Review 3.  Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.

Authors:  Rudolph E Tanzi; Lars Bertram
Journal:  Cell       Date:  2005-02-25       Impact factor: 41.582

4.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.

Authors:  Wendy Noble; Emmanuel Planel; Cindy Zehr; Vicki Olm; Jordana Meyerson; Farhana Suleman; Kate Gaynor; Lili Wang; John LaFrancois; Boris Feinstein; Mark Burns; Pavan Krishnamurthy; Yi Wen; Ratan Bhat; Jada Lewis; Dennis Dickson; Karen Duff
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-02       Impact factor: 11.205

5.  P70 S6 kinase mediates tau phosphorylation and synthesis.

Authors:  Jin-Jing Pei; Wen-Lin An; Xin-Wen Zhou; Takeshi Nishimura; Jan Norberg; Eirikur Benedikz; Jürgen Götz; Bengt Winblad
Journal:  FEBS Lett       Date:  2005-12-06       Impact factor: 4.124

6.  Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity.

Authors:  Alejandra del C Alonso; Bin Li; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-30       Impact factor: 11.205

7.  M1 receptors play a central role in modulating AD-like pathology in transgenic mice.

Authors:  Antonella Caccamo; Salvatore Oddo; Lauren M Billings; Kim N Green; Hilda Martinez-Coria; Abraham Fisher; Frank M LaFerla
Journal:  Neuron       Date:  2006-03-02       Impact factor: 17.173

8.  Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease.

Authors:  Masashi Kitazawa; Salvatore Oddo; Tritia R Yamasaki; Kim N Green; Frank M LaFerla
Journal:  J Neurosci       Date:  2005-09-28       Impact factor: 6.167

9.  Tau suppression in a neurodegenerative mouse model improves memory function.

Authors:  K Santacruz; J Lewis; T Spires; J Paulson; L Kotilinek; M Ingelsson; A Guimaraes; M DeTure; M Ramsden; E McGowan; C Forster; M Yue; J Orne; C Janus; A Mariash; M Kuskowski; B Hyman; M Hutton; K H Ashe
Journal:  Science       Date:  2005-07-15       Impact factor: 47.728

10.  Rapamycin alleviates toxicity of different aggregate-prone proteins.

Authors:  Zdenek Berger; Brinda Ravikumar; Fiona M Menzies; Lourdes Garcia Oroz; Benjamin R Underwood; Menelas N Pangalos; Ina Schmitt; Ullrich Wullner; Bernd O Evert; Cahir J O'Kane; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2005-12-20       Impact factor: 6.150

View more
  56 in total

Review 1.  Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances.

Authors:  Wei-Ye Liu; Zhi-Bin Wang; Li-Chao Zhang; Xin Wei; Ling Li
Journal:  CNS Neurosci Ther       Date:  2012-06-12       Impact factor: 5.243

2.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

3.  PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10.

Authors:  Payal Ray; Amar Kar; Kazuo Fushimi; Necat Havlioglu; Xiaoping Chen; Jane Y Wu
Journal:  J Mol Neurosci       Date:  2011-09-01       Impact factor: 3.444

Review 4.  Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors.

Authors:  Chanung Wang; David M Holtzman
Journal:  Neuropsychopharmacology       Date:  2019-08-13       Impact factor: 7.853

5.  Restoration of lipoxin A4 signaling reduces Alzheimer's disease-like pathology in the 3xTg-AD mouse model.

Authors:  Haley C Dunn; Rahasson R Ager; David Baglietto-Vargas; David Cheng; Masashi Kitazawa; David H Cribbs; Rodrigo Medeiros
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

6.  Restraint stress in rats alters gene transcription and protein translation in the hippocampus.

Authors:  Petra Sántha; Magdolna Pákáski; Orsike Csilla Fazekas; Eszter Klára Fodor; Sára Kálmán; János Kálmán; Zoltán Janka; Gyula Szabó; János Kálmán
Journal:  Neurochem Res       Date:  2012-01-05       Impact factor: 3.996

7.  Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo.

Authors:  Tomas Ondrejcak; Igor Klyubin; Grant T Corbett; Graham Fraser; Wei Hong; Alexandra J Mably; Matthew Gardener; Jayne Hammersley; Michael S Perkinton; Andrew Billinton; Dominic M Walsh; Michael J Rowan
Journal:  J Neurosci       Date:  2018-10-24       Impact factor: 6.167

Review 8.  Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer's disease.

Authors:  Rosella Abeti; Michael R Duchen
Journal:  Neurochem Res       Date:  2012-10-18       Impact factor: 3.996

9.  Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.

Authors:  David Baglietto-Vargas; Rodrigo Medeiros; Hilda Martinez-Coria; Frank M LaFerla; Kim N Green
Journal:  Biol Psychiatry       Date:  2013-01-08       Impact factor: 13.382

10.  5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5.

Authors:  Jin Chu; Domenico Praticò
Journal:  Neurobiol Aging       Date:  2013-01-16       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.